Univariate and multivariate analyses for CIR, NRM, RFS, and OS in 131 patients with AML considering only mutations in non-DTA genes
| . | . | No. of patients . | Events . | 5-y outcome . | Univariate analysis . | Multivariate analysis . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Endpoint . | Variables in the model . | First/ second category . | First/ second category . | % Alive first/second . | HR . | 95% CI . | P . | HR . | 95% CI . | P . |
| CIR | Complex karyotype positive vs negative | 12/119 | 10/35 | 75/28 | 6.44 | 3.03-13.69 | < .001 | 3.08 | 1.11-8.59 | .031 |
| CMV status all other combinations vs D + P negative | 94/37 | 40/5 | 41/11 | 3.83 | 1.51-9.69 | .005 | 3.19 | 1.25-8.11 | .015 | |
| MRD non-DTA positive vs negative | 26/105 | 18/27 | 62/25 | 4.26 | 2.33-7.76 | < .001 | 3.27 | 1.55-6.86 | .002 | |
| NRM | AML type secondary vs de novo | 36/95 | 6/5 | 14/3 | 3.74 | 1.18-11.79 | .024 | 4.45 | 1.48-13.42 | .008 |
| RFS | CMV status all other combination vs D + P negative | 94/37 | 48/8 | 52/84 | 3.03 | 1.45-6.32 | .003 | 3.02 | 1.44-6.31 | .003 |
| MRD non-DTA positive vs negative | 26/105 | 19/37 | 35/68 | 3.58 | 2.00-6.40 | < .001 | 3.57 | 1.95-6.53 | < .001 | |
| OS | Complex karyotype positive vs negative | 12/119 | 9/36 | 22/71 | 6.53 | 2.74-15.54 | < .001 | 4.72 | 1.75-12.75 | .002 |
| CMV status all other combinations vs D + P negative | 94/37 | 39/6 | 60/86 | 3.19 | 1.35-7.54 | .008 | 2.62 | 1.12-6.13 | .026 | |
| N/KRAS mutated vs wild type | 29/102 | 14/31 | 52/71 | 2.06 | 1.12-3.79 | .021 | 2.44 | 1.36-4.40 | .003 | |
| MRD non-DTA positive vs negative | 26/105 | 15/30 | 49/73 | 2.70 | 1.45-5.04 | .002 | 2.18 | 1.09-4.36 | .028 | |
| . | . | No. of patients . | Events . | 5-y outcome . | Univariate analysis . | Multivariate analysis . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Endpoint . | Variables in the model . | First/ second category . | First/ second category . | % Alive first/second . | HR . | 95% CI . | P . | HR . | 95% CI . | P . |
| CIR | Complex karyotype positive vs negative | 12/119 | 10/35 | 75/28 | 6.44 | 3.03-13.69 | < .001 | 3.08 | 1.11-8.59 | .031 |
| CMV status all other combinations vs D + P negative | 94/37 | 40/5 | 41/11 | 3.83 | 1.51-9.69 | .005 | 3.19 | 1.25-8.11 | .015 | |
| MRD non-DTA positive vs negative | 26/105 | 18/27 | 62/25 | 4.26 | 2.33-7.76 | < .001 | 3.27 | 1.55-6.86 | .002 | |
| NRM | AML type secondary vs de novo | 36/95 | 6/5 | 14/3 | 3.74 | 1.18-11.79 | .024 | 4.45 | 1.48-13.42 | .008 |
| RFS | CMV status all other combination vs D + P negative | 94/37 | 48/8 | 52/84 | 3.03 | 1.45-6.32 | .003 | 3.02 | 1.44-6.31 | .003 |
| MRD non-DTA positive vs negative | 26/105 | 19/37 | 35/68 | 3.58 | 2.00-6.40 | < .001 | 3.57 | 1.95-6.53 | < .001 | |
| OS | Complex karyotype positive vs negative | 12/119 | 9/36 | 22/71 | 6.53 | 2.74-15.54 | < .001 | 4.72 | 1.75-12.75 | .002 |
| CMV status all other combinations vs D + P negative | 94/37 | 39/6 | 60/86 | 3.19 | 1.35-7.54 | .008 | 2.62 | 1.12-6.13 | .026 | |
| N/KRAS mutated vs wild type | 29/102 | 14/31 | 52/71 | 2.06 | 1.12-3.79 | .021 | 2.44 | 1.36-4.40 | .003 | |
| MRD non-DTA positive vs negative | 26/105 | 15/30 | 49/73 | 2.70 | 1.45-5.04 | .002 | 2.18 | 1.09-4.36 | .028 | |
HRs >1 or <1 indicate an increased or decreased risk, respectively, of an event for the first category listed.
CI, confidence interval; D + P, donor and patient; HR, hazard ratio; non-DTA, mutation in genes other than DNMT3A, TET2, and ASXL1.